About the Company
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BOLD News
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
Audentes Therapeutics, Inc. BOLD was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands ...
Astellas buys gene therapy company for $3bn
Astellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of approximately $3 billion, adding a new focus area to its drug discovery efforts.
Astellas agrees to buy Audentes in US$3b gene-therapy deal
TOKYO: Astellas Pharma Inc. agreed to buy Audentes Therapeutics Inc. for about $3 billion, the latest deal by a pharmaceutical company eager to push into promising gene-therapy technologies.
Boundless Bio Inc. Common Stock
Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare ...
ATXS Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Louis G Lange's Net Worth
Who is Louis G Lange? Louis G Lange has an estimated net worth of $30 Million. This is based on reported shares across multiple companies, which include GILEAD SCIENCES INC, Epiphany Technology ...
Aquestive Therapeutics, Inc. (AQST)
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company ...
FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high ...
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cargo Therapeutics Inc CRGX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Loading the latest forecasts...